BioSpace News Archive

NewAmsterdam Pharma (NewAmsterdam), today announced new clinical data from post-hoc analyses of its Phase 2b Randomized Study of Obicetrapib as an Adjunct to Statin Therapy (ROSE) clinical trial, showing that patients treated with obicetrapib were more likely to achieve low-density lipoprotein cholesterol (LDL-c) target guideline goals compared to patients treated with placebo.

IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of John Huynh, Ph.D., as the Company’s first Chief Technology Officer.

Charles River Laboratories International, Inc. announced that it will present at the Jefferies Healthcare Conference on Wednesday, June 8th, at 10:00 a.m. ET, and at the William Blair 42nd Annual Growth Stock Conference on Thursday, June 9th, at 10:40 a.m. CT.

Introducing Cantata Bio, Inventive Multimodal Solutions for Accelerating Genome-based R&D.

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Chief Executive Officer, Zachary Hornby, will present at the 2022 Jefferies Healthcare Conference, which will take place in New York City.

ASMS 2022 – Waters Corporation unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry 2022 Annual Conference.

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the JMP Securities Life Sciences Conference, taking place June 15-16, 2022 in New York City.

Novartis today announced Tafinlar® (dabrafenib) + Mekinist® (trametinib) significantly improved efficacy in patients ages 1 to 17 years old with BRAF V600 pediatric low-grade glioma (pLGG) requiring first systemic treatment compared to chemotherapy, the current standard-of-care for these patients.

Today at the Advances in Genome Biology and Technology (AGBT) Conference, DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, announced the launch of the industry’s first solution to enable same-day turnaround for custom q/dPCR assays with a new generation of kits for the SYNTAX System to print both primers and probes in hours.

Thermo Fisher Scientific Inc., the world leader in serving science, is providing proteomics and biopharmaceutical research laboratories with a new micro-pillar array column as part of an end-to-end LC-MS workflow that will simplify complex bottom-up proteomics analyses.